Joseph P. Lyssikatos, Chief Scientific Officer at Enliven Therapeutics ($ELVN), made 27 open market sales of company shares over the past year, totaling about $6.6 million. His most recent $ELVN sale occurred on February 6, 2026. These transactions rank him 1580th among 11,678 insiders by sale value, below the average of $8.6 million across 6.4 trades. Lyssikatos reported no open market purchases in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A | Stock Option (right to buy) | 112500 | $0.00 | 112,500.0000 | 62,093,795 | 9999.99% | 0.18% |
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A | Common Stock | 18750 | $0.00 | 758,938.0000 | 62,093,795 | 2.53% | 0.03% |
| Feb. 6, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 5000 | $29.04 | 740,188.0000 | 62,093,795 | 0.67% | 0.01% |
| Jan. 20, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 14509 | $26.90 | 745,188.0000 | 62,093,795 | 1.91% | 0.02% |
| Jan. 20, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 5491 | $26.37 | 759,697.0000 | 62,093,795 | 0.72% | 0.01% |
| Jan. 8, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 33802 | $24.92 | 856,386.0000 | 62,093,795 | 3.80% | 0.05% |
| Jan. 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 50000 | $29.13 | 765,188.0000 | 62,093,795 | 6.13% | 0.08% |
| Jan. 9, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 41198 | $24.90 | 815,188.0000 | 62,093,795 | 4.81% | 0.07% |
| Jan. 8, 2026 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 7500 | $20.13 | 890,188.0000 | 62,093,795 | 0.84% | 0.01% |
| Dec. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 5000 | $16.84 | 897,688.0000 | 62,093,795 | 0.55% | 0.01% |
| Nov. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 12008 | $22.30 | 903,180.0000 | 62,093,795 | 1.31% | 0.02% |
| Nov. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 492 | $23.09 | 902,688.0000 | 62,093,795 | 0.05% | 0.00% |
| Oct. 20, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 12500 | $22.08 | 915,188.0000 | 62,093,795 | 1.35% | 0.02% |
| Sept. 26, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 4000 | $20.25 | 927,688.0000 | 47,072,532 | 0.43% | 0.01% |
| Sept. 23, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 1500 | $20.03 | 931,688.0000 | 47,072,532 | 0.16% | 0.00% |
| Sept. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 2130 | $20.02 | 933,188.0000 | 47,072,532 | 0.23% | 0.00% |
| Sept. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 4870 | $19.11 | 935,318.0000 | 47,072,532 | 0.52% | 0.01% |
| Aug. 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 5000 | $19.62 | 947,688.0000 | 47,072,532 | 0.52% | 0.01% |
| Aug. 21, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 7500 | $20.01 | 940,188.0000 | 47,072,532 | 0.79% | 0.02% |
| July 21, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 576 | $22.90 | 952,688.0000 | 47,072,532 | 0.06% | 0.00% |
| July 21, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 11924 | $22.26 | 953,264.0000 | 47,072,532 | 1.24% | 0.03% |
| June 20, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 12500 | $21.40 | 965,188.0000 | 47,072,532 | 1.28% | 0.03% |
| June 3, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 7500 | $20.03 | 977,688.0000 | 47,072,532 | 0.76% | 0.02% |
| May 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 5000 | $16.31 | 985,188.0000 | 47,072,532 | 0.50% | 0.01% |
| May 2, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 2470 | $20.01 | 990,188.0000 | 47,072,532 | 0.25% | 0.01% |
| May 1, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 5030 | $20.07 | 992,658.0000 | 47,072,532 | 0.50% | 0.01% |
| April 21, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 4670 | $16.03 | 998,018.0000 | 47,072,532 | 0.47% | 0.01% |
| April 21, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 330 | $16.72 | 997,688.0000 | 47,072,532 | 0.03% | 0.00% |
| March 19, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 12500 | $20.61 | 1,002,688.0000 | 47,072,532 | 1.23% | 0.03% |
| Feb. 6, 2025 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A | Stock Option (right to buy) | 171000 | $0.00 | 171,000.0000 | 47,072,532 | 9999.99% | 0.36% |
| Oct. 18, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 847 | $30.00 | 1,015,188.0000 | 48,267,458 | 0.08% | 0.00% |
| Oct. 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 34289 | $28.12 | 1,019,624.0000 | 48,267,458 | 3.25% | 0.07% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 13167 | $27.96 | 1,054,013.0000 | 48,267,458 | 1.23% | 0.03% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 100 | $28.51 | 1,053,913.0000 | 48,267,458 | 0.01% | 0.00% |
| Oct. 9, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 3589 | $28.52 | 1,016,035.0000 | 48,267,458 | 0.35% | 0.01% |
| Oct. 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 7522 | $27.51 | 1,069,887.0000 | 48,267,458 | 0.70% | 0.02% |
| Oct. 7, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 2707 | $27.61 | 1,067,180.0000 | 48,267,458 | 0.25% | 0.01% |
| Oct. 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 527 | $27.54 | 1,077,409.0000 | 48,267,458 | 0.05% | 0.00% |
| Aug. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 11950 | $22.48 | 1,077,986.0000 | 35,546,215 | 1.10% | 0.03% |
| Aug. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 50 | $23.08 | 1,077,936.0000 | 35,546,215 | 0.00% | 0.00% |
| July 31, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 3099 | $27.56 | 1,089,936.0000 | 35,546,215 | 0.28% | 0.01% |
| July 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 11797 | $26.69 | 1,093,238.0000 | 35,546,215 | 1.07% | 0.03% |
| July 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 203 | $27.43 | 1,093,035.0000 | 35,546,215 | 0.02% | 0.00% |
| July 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 12000 | $22.89 | 1,105,035.0000 | 35,546,215 | 1.07% | 0.03% |
| May 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 9877 | $21.56 | 1,119,158.0000 | 35,546,215 | 0.87% | 0.03% |
| May 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 35,546,215 | 1.07% | 0.03% |
| May 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Stock Option (right to buy) | 12000 | $0.00 | 206,550.0000 | 35,546,215 | 5.49% | 0.03% |
| May 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 2123 | $22.52 | 1,117,035.0000 | 35,546,215 | 0.19% | 0.01% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Stock Option (right to buy) | 12000 | $0.00 | 218,550.0000 | 35,546,215 | 5.20% | 0.03% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 10987 | $17.86 | 1,118,048.0000 | 35,546,215 | 0.97% | 0.03% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 35,546,215 | 1.07% | 0.03% |
| April 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 1013 | $18.48 | 1,117,035.0000 | 35,546,215 | 0.09% | 0.00% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 30000 | $25.04 | 1,117,035.0000 | 35,546,215 | 2.62% | 0.08% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Common Stock | 30000 | $1.12 | 1,147,035.0000 | 35,546,215 | 2.69% | 0.08% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Stock Option (right to buy) | 30000 | $0.00 | 230,550.0000 | 35,546,215 | 11.51% | 0.08% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 9577 | $18.80 | 1,117,106.0000 | 35,546,215 | 0.85% | 0.03% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 2352 | $17.72 | 1,126,683.0000 | 35,546,215 | 0.21% | 0.01% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 35,546,215 | 1.07% | 0.03% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Stock Option (right to buy) | 12000 | $0.00 | 260,550.0000 | 35,546,215 | 4.40% | 0.03% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 71 | $19.36 | 1,117,035.0000 | 35,546,215 | 0.01% | 0.00% |
| Feb. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 10195 | $16.30 | 1,118,840.0000 | 35,546,215 | 0.90% | 0.03% |
| Feb. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 1805 | $17.09 | 1,117,035.0000 | 35,546,215 | 0.16% | 0.01% |
| Feb. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Stock Option (right to buy) | 12000 | $0.00 | 272,550.0000 | 35,546,215 | 4.22% | 0.03% |
| Feb. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 35,546,215 | 1.07% | 0.03% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A | Stock Option (right to buy) | 185000 | $0.00 | 185,000.0000 | 35,546,215 | 9999.99% | 0.52% |
| Jan. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S | Common Stock | 12000 | $15.85 | 1,117,035.0000 | 35,546,215 | 1.06% | 0.03% |
| Jan. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Stock Option (right to buy) | 12000 | $0.00 | 284,550.0000 | 35,546,215 | 4.05% | 0.03% |
| Jan. 29, 2024 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 35,546,215 | 1.07% | 0.03% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 12000 | $0.00 | 296,550.0000 | 0 | 3.89% | 0.00% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 2849 | $14.78 | 1,117,035.0000 | 0 | 0.25% | 0.00% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 9151 | $14.13 | 1,119,884.0000 | 0 | 0.81% | 0.00% |
| Dec. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 0 | 1.07% | 0.00% |
| Dec. 21, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 20 | $0.00 | 315,096.0000 | 0 | 0.01% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 6546 | $0.00 | 308,550.0000 | 0 | 2.08% | 0.00% |
| Dec. 21, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 20 | $1.12 | 1,117,055.0000 | 0 | 0.00% | 0.00% |
| Dec. 21, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 20 | $13.00 | 1,117,035.0000 | 0 | 0.00% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 6546 | $1.12 | 1,123,581.0000 | 0 | 0.59% | 0.00% |
| Dec. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 6546 | $13.07 | 1,117,035.0000 | 0 | 0.58% | 0.00% |
| Dec. 19, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 200 | $0.00 | 323,804.0000 | 0 | 0.06% | 0.00% |
| Dec. 20, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 8688 | $0.00 | 315,116.0000 | 0 | 2.68% | 0.00% |
| Dec. 20, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 8688 | $13.01 | 1,117,035.0000 | 0 | 0.77% | 0.00% |
| Dec. 20, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 8688 | $1.12 | 1,125,723.0000 | 0 | 0.78% | 0.00% |
| Dec. 19, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 200 | $13.00 | 1,117,035.0000 | 0 | 0.02% | 0.00% |
| Dec. 19, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 200 | $1.12 | 1,117,235.0000 | 0 | 0.02% | 0.00% |
| Nov. 3, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 8546 | $1.12 | 1,125,581.0000 | 0 | 0.77% | 0.00% |
| Nov. 3, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 8546 | $0.00 | 324,004.0000 | 0 | 2.57% | 0.00% |
| Nov. 3, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 8546 | $13.08 | 1,117,035.0000 | 0 | 0.76% | 0.00% |
| Sept. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Common Stock | 12000 | $1.12 | 1,129,035.0000 | 0 | 1.07% | 0.00% |
| Sept. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | M | Stock Option (right to buy) | 12000 | $0.00 | 332,550.0000 | 0 | 3.48% | 0.00% |
| Sept. 29, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | S | Common Stock | 12000 | $13.62 | 1,117,035.0000 | 0 | 1.06% | 0.00% |
| April 4, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | A | Stock Option (right to buy) | 206000 | $0.00 | 206,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | A | Common Stock | 1117035 | $0.00 | 1,117,035.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | A | Employee Stock Option (right to buy) | 344550 | $0.00 | 344,550.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Lyssikatos Joseph P | Chief Scientific Officer | A | Employee Stock Option (right to buy) | 88531 | $0.00 | 88,531.0000 | 0 | 9999.99% | 0.00% |